ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Sanofi, Hoffmann-La Roche and CSPC Pharmaceutical Group side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Sanofi×Hoffmann-La Roche×CSPC Pharmaceutical Group×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

SanofiHoffmann-La RocheCSPC Pharmaceutical Group
studies on the registry2,4252,744355
open to participants now105115170
phase 3 studies under way619564
reach primary completion within a year647755
programswith a study of their own in two years81+12 named only80+25 named only68+3 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseSanofiHoffmann-La RocheCSPC Pharmaceutical Group
Phase 128%

Hoffmann-La Roche: 33 of its 80 programs at phase 1

  1. RAY121phase 1
  2. clesitamigphase 1
  3. P-CD19CD20-ALLO1 Cellsphase 1
  4. Anti-c-Met Antibody-drug Conjugate YL211phase 1
  5. Anti-CDH17 Antibody-drug Conjugate HS-20110phase 1

and 28 more — sign in to see them all

41%

CSPC Pharmaceutical Group: 16 of its 68 programs at phase 1

  1. JMT206phase 1
  2. SYH2082phase 1
  3. JMT106phase 1
  4. paclitaxel cationic liposome for injectionphase 1
  5. palbociclibphase 1

and 11 more — sign in to see them all

24%
Phase 2

Sanofi: 25 of its 81 programs at phase 2

  1. brivekimigphase 2
  2. Acne mRNA vaccinephase 2
  3. Daxokafusp Alfaphase 2
  4. RSV+HMPV vaccinephase 2
  5. efdoralprin alfaphase 2

and 20 more — sign in to see them all

31%

Hoffmann-La Roche: 18 of its 80 programs at phase 2

  1. tifeglipronphase 2
  2. autogene cevumeranphase 2
  3. hyaluronidase (human recombinant)phase 2
  4. RO7568282phase 2
  5. tambotatug pelitecanphase 2

and 13 more — sign in to see them all

23%

CSPC Pharmaceutical Group: 26 of its 68 programs at phase 2

  1. Anti-PD-1/IL-15 Fusion Protein JMT108phase 2
  2. SYS6006 COVID-19 vaccinephase 2
  3. ATM Inhibitor SYH2051phase 2
  4. SYH2069phase 2
  5. SYH2070phase 2

and 21 more — sign in to see them all

38%
Phase 3

Sanofi: 22 of its 81 programs at phase 3

  1. rilzabrutinibphase 3
  2. frexalimabphase 3
  3. Pneumococcal 21-Valent Conjugate Vaccinephase 3
  4. lunsekimigphase 3
  5. duvakitugphase 3

and 17 more — sign in to see them all

27%

Hoffmann-La Roche: 22 of its 80 programs at phase 3

  1. inavolisibphase 3
  2. afimkibartphase 3
  3. giredestrantphase 3
  4. divarasibphase 3
  5. glofitamabphase 3

and 17 more — sign in to see them all

28%

CSPC Pharmaceutical Group: 25 of its 68 programs at phase 3

  1. Anti-EGFR Antibody-drug Conjugate CPO301phase 3
  2. Docetaxelphase 3
  3. enlonstobartphase 3
  4. becotatugphase 3
  5. anbenitamabphase 3

and 20 more — sign in to see them all

37%
Approved, new studies

Sanofi: 11 of its 81 programs at approved, new studies

  1. dupilumabapproved, new study
  2. belumosudilapproved, new study
  3. sarilumabapproved, new study
  4. fitusiranapproved, new study
  5. Avapritinibapproved, new study

and 6 more — sign in to see them all

14%

Hoffmann-La Roche: 7 of its 80 programs at approved, new studies

  1. ocrelizumabapproved, new study
  2. Ranibizumabapproved, new study
  3. emicizumabapproved, new study
  4. faricimabapproved, new study
  5. Trastuzumabapproved, new study

and 2 more — sign in to see them all

9%

CSPC Pharmaceutical Group: 1 of its 68 programs at approved, new studies

  1. Tenecteplaseapproved, new study
1%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Sanofi29 readouts · 10 phase 3

Sanofi, Nov ’26: 3 programs whose next study reaches primary completion, 3 in phase 3

  1. rilzabrutinibphase 3 · Nov 25 · NCT07216079
  2. NVX-CoV2373 adjuvated lipid nanoparticleapproved, new study · Nov 26 · NCT07861542
  3. Measles, combinations with mumps and rubella, live attenuatedphase 3 · Nov 28 · NCT07103148

Sanofi, Dec ’26: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. Pandemic flu H5 HA mRNA SD2 vaccinephase 2 · Dec 1 · NCT06907511
  2. Pneumococcal 21-Valent Conjugate Vaccinephase 3 · Dec 1 · NCT06838000
  3. brivekimigphase 2 · Dec 17 · NCT06958536
  4. frexalimabphase 3 · Dec 23 · NCT06500702

Sanofi, Jan ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. efanesoctocog alfaapproved, new study · Jan 15 · NCT04644575
  2. RSV+HMPV vaccinephase 2 · Jan 18 · NCT06686654
  3. Daxokafusp Alfaphase 2 · Jan 19 · NCT05584670
  4. belumosudilapproved, new study · Jan 26 · NCT07726914
  5. rF1V-1018phase 2 · Jan 29 · NCT07207408

Sanofi, Feb ’27: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. dupilumabapproved, new study · Feb 7 · NCT07905547
  2. itepekimabphase 3 · Feb 17 · NCT07424144

Sanofi, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. fitusiranapproved, new study · Mar 25 · NCT05662319

Sanofi, Apr ’27: 6 programs whose next study reaches primary completion

  1. H5 Flu IMP 2phase 1 · Apr 4 · NCT07516418
  2. Inosine Monophosphatephase 1 · Apr 4 · NCT07516418
  3. RSV IMP 4phase 1 · Apr 4 · NCT07516418
  4. RSV IMP 5phase 1 · Apr 4 · NCT07516418
  5. RSV IMP 6phase 1 · Apr 4 · NCT07516418

and 1 more — sign in to see them all

Sanofi, May ’27: 1 program whose next study reaches primary completion

  1. SAR402663phase 2 · May 18 · NCT06660667

Sanofi, Jun ’27: 2 programs whose next study reaches primary completion

  1. lunsekimigphase 3 · Jun 21 · NCT06676319
  2. Avapritinibapproved, new study · Jun 23 · NCT03731260

Sanofi, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. riliprubartphase 3 · Jul 9 · NCT06290141

Sanofi, Aug ’27: 1 program whose next study reaches primary completion

  1. SAR448632phase 1 · Aug 15 · NCT07944885

Sanofi, Sep ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. zetrukibartphase 2 · Sep 22 · NCT07225569
  2. amlitelimabphase 3 · Sep 30 · NCT06241118

Sanofi, Oct ’27: 1 program whose next study reaches primary completion

  1. SAR446597phase 2 · Oct 13 · NCT07215234
Hoffmann-La Roche28 readouts · 7 phase 3

Hoffmann-La Roche, Nov ’26: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. emicizumabapproved, new study · Nov 19 · NCT05181618
  2. nivegacetorphase 2 · Nov 19 · NCT06402838
  3. divarasibphase 3 · Nov 30 · NCT04302025

Hoffmann-La Roche, Dec ’26: 4 programs whose next study reaches primary completion

  1. RG6496phase 1 · Dec 1 · NCT07246941
  2. tifeglipronphase 2 · Dec 7 · NCT06982131
  3. afimkibartphase 3 · Dec 31 · NCT05910528
  4. inavolisibphase 3 · Dec 31 · NCT03006172

Hoffmann-La Roche, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. faricimabapproved, new study · Jan 26 · NCT05224102

Hoffmann-La Roche, Feb ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. Ranibizumabapproved, new study · Feb 4 · NCT04657289
  2. cevostamabphase 3 · Feb 26 · NCT05535244

Hoffmann-La Roche, Mar ’27: 4 programs whose next study reaches primary completion

  1. pegozaferminphase 3 · Mar 2 · NCT07835243
  2. glofitamabphase 3 · Mar 22 · NCT06624085
  3. RAY121phase 1 · Mar 31 · NCT06371417
  4. RO7812653phase 1 · Mar 31 · NCT07234942

Hoffmann-La Roche, Apr ’27: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. enicepatidephase 3 · Apr 8 · NCT07626515
  2. Crovalimabphase 3 · Apr 18 · NCT04432584
  3. baloxavirphase 3 · Apr 30 · NCT07827599

Hoffmann-La Roche, May ’27: 1 program whose next study reaches primary completion

  1. RO7806881phase 1 · May 11 · NCT07271693

Hoffmann-La Roche, Jun ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. fenebrutinibphase 3 · Jun 8 · NCT07161258
  2. DONQ52phase 2 · Jun 15 · NCT07239336
  3. RO7890597phase 1 · Jun 15 · NCT07797478
  4. astegolimabphase 3 · Jun 30 · NCT05878769

Hoffmann-La Roche, Jul ’27: 2 programs whose next study reaches primary completion

  1. giredestrantphase 3 · Jul 31 · NCT03332797
  2. trontinemabphase 3 · Jul 31 · NCT04639050

Hoffmann-La Roche, Aug ’27: 2 programs whose next study reaches primary completion

  1. RO7837195phase 2 · Aug 25 · NCT06979336
  2. bizrolertinibphase 3 · Aug 31 · NCT05593094

Hoffmann-La Roche, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. zemocimigphase 3 · Sep 23 · NCT07416526

Hoffmann-La Roche, Oct ’27: 1 program whose next study reaches primary completion

  1. mosunetuzumabphase 3 · Oct 1 · NCT05207670
CSPC Pharmaceutical Group39 readouts · 6 phase 3

CSPC Pharmaceutical Group, Nov ’26: 3 programs whose next study reaches primary completion

  1. SYH2061phase 1 · Nov 24 · NCT07241910
  2. Anti-EGFR Antibody-drug Conjugate CPO301phase 3 · Nov 30 · NCT07256509
  3. Anti-PD-1/IL-15 Fusion Protein JMT108phase 2 · Nov 30 · NCT07280832

CSPC Pharmaceutical Group, Dec ’26: 6 programs whose next study reaches primary completion, 2 in phase 3

  1. anbenitamabphase 3 · Dec 16 · NCT06747338
  2. Docetaxelphase 3 · Dec 16 · NCT06747338
  3. glumetinibphase 3 · Dec 25 · NCT06525350
  4. paliperidoneno phase · Dec 31 · NCT07493551
  5. SYH2059phase 2 · Dec 31 · NCT07510958

and 1 more — sign in to see them all

CSPC Pharmaceutical Group, Jan ’27: 4 programs whose next study reaches primary completion

  1. SYH2056phase 1 · Jan 30 · NCT07771777
  2. SYH2082phase 1 · Jan 30 · NCT07532655
  3. SYS6005phase 1 · Jan 30 · NCT06958679
  4. SYH2062phase 2 · Jan 31 · NCT07940075

CSPC Pharmaceutical Group, Feb ’27: 4 programs whose next study reaches primary completion

  1. SYH2072phase 2 · Feb 1 · NCT07647783
  2. SYH2092phase 1 · Feb 9 · NCT07776041
  3. JMT206phase 1 · Feb 28 · NCT07840729
  4. SYS6040phase 1 · Feb 28 · NCT06970795

CSPC Pharmaceutical Group, Mar ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. A zoster mRNA vaccine SYS6017phase 2 · Mar 10 · NCT07354659
  2. becotatugphase 3 · Mar 26 · NCT06380348
  3. SYS6041phase 2 · Mar 28 · NCT07744763

CSPC Pharmaceutical Group, Apr ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. enlonstobartphase 3 · Apr 0 · NCT06136988
  2. CPO-107phase 2 · Apr 1 · NCT07029139
  3. SYHX1901phase 3 · Apr 28 · NCT06943950
  4. SYH2070phase 2 · Apr 30 · NCT07695597
  5. SYH2085phase 2 · Apr 30 · NCT07798193

CSPC Pharmaceutical Group, May ’27: 1 program whose next study reaches primary completion

  1. anbenitamab repodatecanphase 3 · May 29 · NCT07545044

CSPC Pharmaceutical Group, Jun ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. ATM Inhibitor SYH2051phase 2 · Jun 15 · NCT06775236
  2. bempedoic acidphase 3 · Jun 30 · NCT07623915

CSPC Pharmaceutical Group, Jul ’27: 4 programs whose next study reaches primary completion

  1. ocankitugphase 3 · Jul 1 · NCT07418736
  2. SYH2053phase 3 · Jul 15 · NCT07938034
  3. SYS6045phase 2 · Jul 30 · NCT07122063
  4. CHO cellphase 2 · Jul 31 · NCT07892989

CSPC Pharmaceutical Group, Aug ’27: 2 programs whose next study reaches primary completion

  1. SYHX2008phase 3 · Aug 1 · NCT06505395
  2. JMT203phase 2 · Aug 14 · NCT06868849

CSPC Pharmaceutical Group, Sep ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. Aripiprazoleno phase · Sep 5 · NCT07547384
  2. SYH2069phase 2 · Sep 28 · NCT07796477
  3. Tenecteplaseapproved, new study · Sep 30 · NCT07201688

CSPC Pharmaceutical Group, Oct ’27: 2 programs whose next study reaches primary completion

  1. palbociclibphase 1 · Oct 0 · NCT06941142
  2. Sirolimusphase 3 · Oct 0 · NCT06941142
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Sanofi

New programs 6

Reached a new phase 1

Study stopped 4

  • balinatunfibphase 2 · terminated Oct 22 · none of its studies left running“Business decision” · NCT07222189
  • balinatunfibphase 2 · terminated Oct 21 · none of its studies left running“Business decision” · NCT06867094
  • balinatunfibphase 2 · terminated Oct 13 · none of its studies left running“Business decision.” · NCT06637631
  • amlitelimabphase 2 · terminated Oct 2“Sponsor decision; the decision is not related to any safety concern.” · NCT06033833

Primary completion later 2

Hoffmann-La Roche

New programs 4

  • RO7836748phase 1 · first study · Oct 23
  • RO7821657phase 1 · first study · Oct 14
  • RO7965032phase 2 · first study · Sep 25 · Geographic Atrophy
  • RO7830698phase 2 · first study · Sep 11 · Pulmonary Disease, Chronic Obstructive

Reached a new phase 1

Study stopped 1

  • RO7763505phase 1 · terminated Nov 17 · none of its studies left running“The development of RO7763505 for coronary artery disease has been discontinued.” · NCT07495813

Primary completion later 11

CSPC Pharmaceutical Group

New programs 6

  • SYH9061phase 2 · first study · Nov 2 · Idiopathic Pulmonary Fibrosis
  • SYS6062phase 2 · first study · Oct 20 · Stomach Neoplasms
  • CHO cellphase 2 · first study · Oct 19 · COVID-19
  • SYH2066phase 2 · first study · Oct 11 · Respiratory Syncytial Virus Infections
  • Generic Drugphase 3 · first study · Sep 28 · Triple Negative Breast Neoplasms
  • SYS6088phase 2 · first study · Sep 20 · Neoplasms

Reached a new phase 3

  • SYH2072phase 2 · Oct 28 · Hyperaldosteronism
  • SYH2069phase 2 · Aug 25 · Obesity
  • SYH2085phase 2 · Aug 25 · Influenza, Human

Study stopped 0

None

Primary completion later 2

Where they overlap

Conditions where at least two of them have programs: 54 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionSanofiHoffmann-La RocheCSPC Pharmaceutical Group
Carcinoma, Non-Small-Cell Lungall three · compare here

Sanofi in Carcinoma, Non-Small-Cell Lung: 1 program

  1. Tadalafilphase 3

Their studies: Sanofi’s studies of Carcinoma, Non-Small-Cell Lung in search

Hoffmann-La Roche in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. divarasibphase 3
  2. tambotatug pelitecanphase 2
  3. AQUA07phase 1
  4. lorlatinibphase 1

Their studies: Hoffmann-La Roche’s studies of Carcinoma, Non-Small-Cell Lung in search

CSPC Pharmaceutical Group in Carcinoma, Non-Small-Cell Lung: 10 programs

  1. Anti-EGFR Antibody-drug Conjugate CPO301phase 3
  2. Docetaxelphase 3
  3. enlonstobartphase 3
  4. becotatugphase 3
  5. glumetinibphase 3

and 5 more — sign in to see them all

Their studies: CSPC Pharmaceutical Group’s studies of Carcinoma, Non-Small-Cell Lung in search

Influenza, Humanall three · compare here

Hoffmann-La Roche in Influenza, Human: 1 program

  1. baloxavirphase 3

Their studies: Hoffmann-La Roche’s studies of Influenza, Human in search

CSPC Pharmaceutical Group in Influenza, Human: 1 program

  1. SYH2085phase 2

Their studies: CSPC Pharmaceutical Group’s studies of Influenza, Human in search

Colorectal Neoplasmsall three · compare here

Sanofi in Colorectal Neoplasms: 1 program

  1. tusamitamab sonditecanphase 1

Their studies: Sanofi’s studies of Colorectal Neoplasms in search

Hoffmann-La Roche in Colorectal Neoplasms: 5 programs

  1. inavolisibphase 3
  2. divarasibphase 3
  3. autogene cevumeranphase 2
  4. Lead Pb 203-DOTAMphase 1
  5. Trastuzumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Colorectal Neoplasms in search

CSPC Pharmaceutical Group in Colorectal Neoplasms: 4 programs

  1. becotatugphase 3
  2. anbenitamab repodatecanphase 3
  3. Anti-PD-1/IL-15 Fusion Protein JMT108phase 2
  4. sintilimabphase 2

Their studies: CSPC Pharmaceutical Group’s studies of Colorectal Neoplasms in search

Dermatitis, Atopicall three · compare here

Sanofi in Dermatitis, Atopic: 5 programs

  1. lunsekimigphase 3
  2. amlitelimabphase 3
  3. itepekimabphase 3
  4. Dupilumab coformulated with berahyaluronidase alfaphase 3
  5. dupilumabapproved, new study

Their studies: Sanofi’s studies of Dermatitis, Atopic in search

Hoffmann-La Roche in Dermatitis, Atopic: 3 programs

  1. afimkibartphase 3
  2. astegolimabphase 3
  3. Cyclosporineapproved, new study

Their studies: Hoffmann-La Roche’s studies of Dermatitis, Atopic in search

CSPC Pharmaceutical Group in Dermatitis, Atopic: 1 program

  1. ocankitugphase 3

Their studies: CSPC Pharmaceutical Group’s studies of Dermatitis, Atopic in search

Stomach Neoplasmsall three · compare here

Sanofi in Stomach Neoplasms: 1 program

  1. Daxokafusp Alfaphase 2

Their studies: Sanofi’s studies of Stomach Neoplasms in search

Hoffmann-La Roche in Stomach Neoplasms: 1 program

  1. Trastuzumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Stomach Neoplasms in search

CSPC Pharmaceutical Group in Stomach Neoplasms: 7 programs

  1. Docetaxelphase 3
  2. enlonstobartphase 3
  3. anbenitamabphase 3
  4. anbenitamab repodatecanphase 3
  5. trastuzumab envedotinphase 3

and 2 more — sign in to see them all

Their studies: CSPC Pharmaceutical Group’s studies of Stomach Neoplasms in search

Asthmaall three · compare here

Sanofi in Asthma: 5 programs

  1. lunsekimigphase 3
  2. duvakitugphase 3
  3. amlitelimabphase 3
  4. itepekimabphase 3
  5. dupilumabapproved, new study

Their studies: Sanofi’s studies of Asthma in search

Hoffmann-La Roche in Asthma: 1 program

  1. astegolimabphase 3

Their studies: Hoffmann-La Roche’s studies of Asthma in search

CSPC Pharmaceutical Group in Asthma: 1 program

  1. ocankitugphase 3

Their studies: CSPC Pharmaceutical Group’s studies of Asthma in search

COVID-19all three · compare here

Sanofi in COVID-19: 3 programs

  1. NVX-COV2705phase 3
  2. Biological Productsphase 1
  3. NVX-CoV2373 adjuvated lipid nanoparticleapproved, new study

Their studies: Sanofi’s studies of COVID-19 in search

Hoffmann-La Roche in COVID-19: 1 program

  1. astegolimabphase 3

Their studies: Hoffmann-La Roche’s studies of COVID-19 in search

CSPC Pharmaceutical Group in COVID-19: 3 programs

  1. SYS6006 COVID-19 vaccinephase 2
  2. CHO cellphase 2
  3. palbociclibphase 1

Their studies: CSPC Pharmaceutical Group’s studies of COVID-19 in search

Diabetes Mellitus, Type 2all three · compare here

Sanofi in Diabetes Mellitus, Type 2: 1 program

  1. iGlarLixi (insulin glargine/lixisenatide)approved, new study

Their studies: Sanofi’s studies of Diabetes Mellitus, Type 2 in search

Hoffmann-La Roche in Diabetes Mellitus, Type 2: 3 programs

  1. enicepatidephase 3
  2. emugrobartphase 3
  3. tifeglipronphase 2

Their studies: Hoffmann-La Roche’s studies of Diabetes Mellitus, Type 2 in search

CSPC Pharmaceutical Group in Diabetes Mellitus, Type 2: 2 programs

  1. edaglutide alfaphase 3
  2. SYH2069phase 2

Their studies: CSPC Pharmaceutical Group’s studies of Diabetes Mellitus, Type 2 in search

Pulmonary Disease, Chronic Obstructiveall three · compare here

Sanofi in Pulmonary Disease, Chronic Obstructive: 3 programs

  1. lunsekimigphase 3
  2. itepekimabphase 3
  3. dupilumabapproved, new study

Their studies: Sanofi’s studies of Pulmonary Disease, Chronic Obstructive in search

Hoffmann-La Roche in Pulmonary Disease, Chronic Obstructive: 2 programs

  1. astegolimabphase 3
  2. RO7830698phase 2

Their studies: Hoffmann-La Roche’s studies of Pulmonary Disease, Chronic Obstructive in search

CSPC Pharmaceutical Group in Pulmonary Disease, Chronic Obstructive: 1 program

  1. ocankitugphase 3

Their studies: CSPC Pharmaceutical Group’s studies of Pulmonary Disease, Chronic Obstructive in search

Lymphoma, B-Cellall three · compare here

Sanofi in Lymphoma, B-Cell: 1 program

  1. Anti-CD20 Bispecific Antibody DR-0201phase 1

Their studies: Sanofi’s studies of Lymphoma, B-Cell in search

Hoffmann-La Roche in Lymphoma, B-Cell: 3 programs

  1. glofitamabphase 3
  2. mosunetuzumabphase 3
  3. bexobrutidegno phase

Their studies: Hoffmann-La Roche’s studies of Lymphoma, B-Cell in search

CSPC Pharmaceutical Group in Lymphoma, B-Cell: 1 program

  1. CPO-107phase 2

Their studies: CSPC Pharmaceutical Group’s studies of Lymphoma, B-Cell in search

Nasal Polypsall three · compare here

Sanofi in Nasal Polyps: 3 programs

  1. lunsekimigphase 3
  2. itepekimabphase 3
  3. dupilumabapproved, new study

Their studies: Sanofi’s studies of Nasal Polyps in search

Hoffmann-La Roche in Nasal Polyps: 1 program

  1. astegolimabphase 3

Their studies: Hoffmann-La Roche’s studies of Nasal Polyps in search

CSPC Pharmaceutical Group in Nasal Polyps: 1 program

  1. ocankitugphase 3

Their studies: CSPC Pharmaceutical Group’s studies of Nasal Polyps in search

Breast Neoplasms2 of 3 · compare here–

Hoffmann-La Roche in Breast Neoplasms: 6 programs

  1. inavolisibphase 3
  2. giredestrantphase 3
  3. bizrolertinibphase 3
  4. vustanaciclibphase 2
  5. GDC-0587phase 1

and 1 more — sign in to see them all

Their studies: Hoffmann-La Roche’s studies of Breast Neoplasms in search

CSPC Pharmaceutical Group in Breast Neoplasms: 10 programs

  1. Anti-EGFR Antibody-drug Conjugate CPO301phase 3
  2. Docetaxelphase 3
  3. anbenitamabphase 3
  4. Sirolimusphase 3
  5. anbenitamab repodatecanphase 3

and 5 more — sign in to see them all

Their studies: CSPC Pharmaceutical Group’s studies of Breast Neoplasms in search

Show all 54

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Sanofi 54 of 81 · Hoffmann-La Roche 40 of 80 · CSPC Pharmaceutical Group 25 of 68 programs (44 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Sanofi: 12, Hoffmann-La Roche: 25, CSPC Pharmaceutical Group: 3).